{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:18:16Z","timestamp":1791260296534,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T00:00:00Z","timestamp":1547424000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Chem Biol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1038\/s41589-018-0204-3","type":"journal-article","created":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T09:31:55Z","timestamp":1546853515000},"page":"250-258","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":136,"title":["Selective and reversible modification of kinase cysteines with chlorofluoroacetamides"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2374-9896","authenticated-orcid":false,"given":"Naoya","family":"Shindo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Fuchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mami","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Watari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Kuwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chizuru","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Hatsuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6871-522X","authenticated-orcid":false,"given":"Seiichi","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsunori","family":"Shiroishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5568-2369","authenticated-orcid":false,"given":"Jose M. M.","family":"Caaveiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1648-9296","authenticated-orcid":false,"given":"Tomonori","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaharu","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Koyanagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehiro","family":"Ohdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuchika","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Hamachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9440-8167","authenticated-orcid":false,"given":"Akio","family":"Ojida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,14]]},"reference":[{"key":"204_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1021\/jm8008597","volume":"52","author":"MH Potashman","year":"2009","unstructured":"Potashman, M. H. & Duggan, M. E. Covalent modifiers: an orthogonal approach to drug design. J. Med. Chem. 52, 1231\u20131246 (2009).","journal-title":"J. Med. Chem."},{"key":"204_CR2","doi-asserted-by":"publisher","first-page":"949","DOI":"10.4155\/fmc.10.21","volume":"2","author":"DS Johnson","year":"2010","unstructured":"Johnson, D. S., Weerapana, E. & Cravatt, B. F. Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. Future Med. Chem. 2, 949\u2013964 (2010).","journal-title":"Future Med. Chem."},{"key":"204_CR3","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrd3410","volume":"10","author":"J Singh","year":"2011","unstructured":"Singh, J., Petter, R. C., Baillie, T. A. & Whitty, A. The resurgence of covalent drugs. Nat. Rev. Drug. Discov. 10, 307\u2013317 (2011).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"204_CR4","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1021\/jm3008745","volume":"56","author":"M Nacht","year":"2013","unstructured":"Nacht, M. et al. Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3K\u03b1. J. Med. Chem. 56, 712\u2013721 (2013).","journal-title":"J. Med. Chem."},{"key":"204_CR5","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1074\/jbc.M114.595181","volume":"290","author":"ER Goedken","year":"2015","unstructured":"Goedken, E. R. et al. Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol. J. Biol. Chem. 290, 4573\u20134589 (2015).","journal-title":"J. Biol. Chem."},{"key":"204_CR6","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.chembiol.2016.10.008","volume":"23","author":"M Forster","year":"2016","unstructured":"Forster, M. et al. Selective JAK3 inhibitors with a covalent reversible binding mode targeting a new induced fit binding pocket. Cell Chem. Biol. 23, 1335\u20131340 (2016).","journal-title":"Cell Chem. Biol."},{"key":"204_CR7","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1021\/tx400301q","volume":"26","author":"UP Dahal","year":"2013","unstructured":"Dahal, U. P., Obach, R. S. & Gilbert, A. M. Benchmarking in vitro covalent binding burden as a tool to assess potential toxicity caused by nonspecific covalent binding of covalent drugs. Chem. Res. Toxicol. 26, 1739\u20131745 (2013).","journal-title":"Chem. Res. Toxicol."},{"key":"204_CR8","doi-asserted-by":"publisher","first-page":"13408","DOI":"10.1002\/anie.201601091","volume":"55","author":"TA Baillie","year":"2016","unstructured":"Baillie, T. A. Targeted covalent inhibitors for drug design. Angew. Chem. Int. Ed. Engl. 55, 13408\u201313421 (2016).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"204_CR9","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.cbpa.2010.06.168","volume":"14","author":"J Singh","year":"2010","unstructured":"Singh, J., Petter, R. C. & Kluge, A. F. Targeted covalent drugs of the kinase family. Curr. Opin. Chem. Biol. 14, 475\u2013480 (2010).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"204_CR10","doi-asserted-by":"publisher","first-page":"6243","DOI":"10.1021\/jm3003203","volume":"55","author":"T Barf","year":"2012","unstructured":"Barf, T. & Kaptein, A. Irreversible protein kinase inhibitors: balancing the benefits and risks. J. Med. Chem. 55, 6243\u20136262 (2012).","journal-title":"J. Med. Chem."},{"key":"204_CR11","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.chembiol.2012.12.006","volume":"20","author":"Q Liu","year":"2013","unstructured":"Liu, Q. et al. Developing irreversible inhibitors of the protein kinase cysteinome. Chem. Biol. 20, 146\u2013159 (2013).","journal-title":"Chem. Biol."},{"key":"204_CR12","doi-asserted-by":"publisher","first-page":"4702","DOI":"10.1038\/onc.2008.109","volume":"27","author":"D Li","year":"2008","unstructured":"Li, D. et al. BIBW2992, an irreversible EGFR\/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27, 4702\u20134711 (2008).","journal-title":"Oncogene"},{"key":"204_CR13","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","volume":"4","author":"DAE Cross","year":"2014","unstructured":"Cross, D. A. E. et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 4, 1046\u20131061 (2014).","journal-title":"Cancer Discov."},{"key":"204_CR14","doi-asserted-by":"publisher","first-page":"8249","DOI":"10.1021\/jm500973a","volume":"57","author":"MRV Finlay","year":"2014","unstructured":"Finlay, M. R. V. et al. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J. Med. Chem. 57, 8249\u20138267 (2014).","journal-title":"J. Med. Chem."},{"key":"204_CR15","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","volume":"2","author":"W Pao","year":"2005","unstructured":"Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS. Med. 2, e73 (2005).","journal-title":"PLoS. Med."},{"key":"204_CR16","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1056\/NEJMoa044238","volume":"352","author":"S Kobayashi","year":"2005","unstructured":"Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786\u2013792 (2005).","journal-title":"N. Engl. J. Med."},{"key":"204_CR17","doi-asserted-by":"publisher","first-page":"10072","DOI":"10.1021\/jm501412a","volume":"57","author":"ME Flanagan","year":"2014","unstructured":"Flanagan, M. E. et al. Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors. J. Med. Chem. 57, 10072\u201310079 (2014).","journal-title":"J. Med. Chem."},{"key":"204_CR18","doi-asserted-by":"publisher","first-page":"7590","DOI":"10.1021\/jm5006918","volume":"57","author":"C J\u00f6st","year":"2014","unstructured":"J\u00f6st, C., Nitsche, C., Scholz, T., Roux, L. & Klein, C. D. Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments. J. Med. Chem. 57, 7590\u20137599 (2014).","journal-title":"J. Med. Chem."},{"key":"204_CR19","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nchembio.925","volume":"8","author":"IM Serafimova","year":"2012","unstructured":"Serafimova, I. M. et al. Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles. Nat. Chem. Biol. 8, 471\u2013476 (2012).","journal-title":"Nat. Chem. Biol."},{"key":"204_CR20","doi-asserted-by":"publisher","first-page":"10299","DOI":"10.1021\/ja303436y","volume":"134","author":"PMSD Cal","year":"2012","unstructured":"Cal, P. M. S. D. et al. Iminoboronates: a new strategy for reversible protein modification. J. Am. Chem. Soc. 134, 10299\u201310305 (2012).","journal-title":"J. Am. Chem. Soc."},{"key":"204_CR21","doi-asserted-by":"publisher","first-page":"12624","DOI":"10.1021\/ja505194w","volume":"136","author":"S Krishnan","year":"2014","unstructured":"Krishnan, S. et al. Design of reversible, cysteine-targeted Michael acceptors guided by kinetic and computational analysis. J. Am. Chem. Soc. 136, 12624\u201312630 (2014).","journal-title":"J. Am. Chem. Soc."},{"key":"204_CR22","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nchembio.2174","volume":"12","author":"G Ak\u00e7ay","year":"2016","unstructured":"Ak\u00e7ay, G. et al. Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain. Nat. Chem. Biol. 12, 931\u2013936 (2016).","journal-title":"Nat. Chem. Biol."},{"key":"204_CR23","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.cbpa.2016.08.011","volume":"34","author":"A Bandyopadhyay","year":"2016","unstructured":"Bandyopadhyay, A. & Gao, J. Targeting biomolecules with reversible covalent chemistry. Curr. Opin. Chem. Biol. 34, 110\u2013116 (2016).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"204_CR24","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/nchembio.1582","volume":"10","author":"BR Lanning","year":"2014","unstructured":"Lanning, B. R. et al. A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors. Nat. Chem. Biol. 10, 760\u2013767 (2014).","journal-title":"Nat. Chem. Biol."},{"key":"204_CR25","first-page":"1388","volume":"24","author":"S Niessen","year":"2017","unstructured":"Niessen, S. et al. Proteome-wide map of targets of T790M-EGFR-directed covalent inhibitors. Cell. Chem. Biol. 24, 1388\u20131400.e7 (2017).","journal-title":"Chem. Biol."},{"key":"204_CR26","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nature18002","volume":"534","author":"KM Backus","year":"2016","unstructured":"Backus, K. M. et al. Proteome-wide covalent ligand discovery in native biological systems. Nature 534, 570\u2013574 (2016).","journal-title":"Nature"},{"key":"204_CR27","doi-asserted-by":"publisher","first-page":"14832","DOI":"10.1021\/jacs.6b08656","volume":"138","author":"T Kobayashi","year":"2016","unstructured":"Kobayashi, T., Hoppmann, C., Yang, B. & Wang, L. Using protein-confined proximity to determine chemical reactivity. J. Am. Chem. Soc. 138, 14832\u201314835 (2016).","journal-title":"J. Am. Chem. Soc."},{"key":"204_CR28","doi-asserted-by":"publisher","first-page":"9301","DOI":"10.1021\/ja910703v","volume":"132","author":"H Nonaka","year":"2010","unstructured":"Nonaka, H., Fujishima, S. H., Uchinomiya, S. H., Ojida, A. & Hamachi, I. Selective covalent labeling of tag-fused GPCR proteins on live cell surface with a synthetic probe for their functional analysis. J. Am. Chem. Soc. 132, 9301\u20139309 (2010).","journal-title":"J. Am. Chem. Soc."},{"key":"204_CR29","doi-asserted-by":"publisher","first-page":"4645","DOI":"10.1021\/ja01075a025","volume":"86","author":"FG Bordwell","year":"1964","unstructured":"Bordwell, F. G. & Brannen, W. T. Jr. The effect of the carbonyl and related groups on the reactivity of halides in SN2 reactions. J. Am. Chem. Soc. 86, 4645\u20134650 (1964).","journal-title":"J. Am. Chem. Soc."},{"key":"204_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/onc.2012.21","volume":"32","author":"S Yoshikawa","year":"2013","unstructured":"Yoshikawa, S. et al. Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor. Oncogene 32, 27\u201338 (2013).","journal-title":"Oncogene"},{"key":"204_CR31","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1146\/annurev.biochem.75.101304.124125","volume":"77","author":"BF Cravatt","year":"2008","unstructured":"Cravatt, B. F., Wright, A. T. & Kozarich, J. W. Activity-based protein profiling: from enzyme chemistry to proteomic chemistry. Annu. Rev. Biochem. 77, 383\u2013414 (2008).","journal-title":"Annu. Rev. Biochem."},{"key":"204_CR32","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1073\/pnas.1313733111","volume":"111","author":"PA Schwartz","year":"2014","unstructured":"Schwartz, P. A. et al. Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance. Proc. Natl. Acad. Sci. USA 111, 173\u2013178 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"204_CR33","doi-asserted-by":"crossref","unstructured":"Yoshimatsu, M., Kawamoto, M. & Gotoh, K. First Lewis acid catalyzed generation and reaction of \u03b1-organylsulfanyl and \u03b1-organylselanyl carbenium ions using ethyl \u03b1-fluoroacetate derivatives. Eur. J. Org. Chem. 2884\u20132887 (2005).","DOI":"10.1002\/ejoc.200500179"},{"key":"204_CR34","doi-asserted-by":"publisher","first-page":"13075","DOI":"10.1073\/pnas.1004594107","volume":"107","author":"LA Honigberg","year":"2010","unstructured":"Honigberg, L. A. et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl. Acad. Sci. U.S.A. 107, 13075\u201313080 (2010).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"204_CR35","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nchembio.1817","volume":"11","author":"JM Bradshaw","year":"2015","unstructured":"Bradshaw, J. M. et al. Prolonged and tunable residence time using reversible covalent kinase inhibitors. Nat. Chem. Biol. 11, 525\u2013531 (2015).","journal-title":"Nat. Chem. Biol."},{"key":"204_CR36","doi-asserted-by":"publisher","first-page":"9171","DOI":"10.1021\/acs.jmedchem.5b01018","volume":"58","author":"VJ Cee","year":"2015","unstructured":"Cee, V. J. et al. Systematic study of the glutathione (GSH) reactivity of N-arylacrylamides: 1. Effects of aryl substitution. J. Med. Chem. 58, 9171\u20139178 (2015).","journal-title":"J. Med. Chem."},{"key":"204_CR37","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.1021\/ja01599a021","volume":"78","author":"ET McBee","year":"1956","unstructured":"McBee, E. T., Christman, D. L., Johnson, R. W. Jr & Roberts, C. W. Rates of reaction of some halogen-containing esters with potassium iodide in dry acetone. J. Am. Chem. Soc. 78, 4595\u20134596 (1956).","journal-title":"J. Am. Chem. Soc."},{"key":"204_CR38","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1021\/ja00055a034","volume":"115","author":"KB Wiberg","year":"1993","unstructured":"Wiberg, K. B. & Rablen, P. R. Origin of the stability of carbon tetrafluoride: negative hyperconjugation reexamined. J. Am. Chem. Soc. 115, 614\u2013625 (1993).","journal-title":"J. Am. Chem. Soc."},{"key":"204_CR39","first-page":"308","volume":"37","author":"D O\u2019Hagan","year":"2008","unstructured":"O\u2019Hagan, D. Understanding organofluorine chemistry. An introduction to the C-F bond. Chem. Soc. Rev. 37, 308\u2013319 (2008).","journal-title":"An introduction to the C-F bond. Chem. Soc. Rev."},{"key":"204_CR40","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nature09472","volume":"468","author":"E Weerapana","year":"2010","unstructured":"Weerapana, E. et al. Quantitative reactivity profiling predicts functional cysteines in proteomes. Nature 468, 790\u2013795 (2010).","journal-title":"Nature"},{"key":"204_CR41","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/nchembio.2166","volume":"12","author":"T Zhang","year":"2016","unstructured":"Zhang, T. et al. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat. Chem. Biol. 12, 876\u2013884 (2016).","journal-title":"Nat. Chem. Biol."},{"key":"204_CR42","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/227680a0","volume":"227","author":"UK Laemmli","year":"1970","unstructured":"Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680\u2013685 (1970).","journal-title":"Nature"},{"key":"204_CR43","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1021\/ml300327z","volume":"4","author":"S Sogabe","year":"2012","unstructured":"Sogabe, S. et al. Structure-based approach for the discovery of pyrrolo[3,2-d]pyrimidine-based EGFR T790M\/L858R mutant inhibitors. ACS Med. Chem. Lett. 4, 201\u2013205 (2012).","journal-title":"ACS Med. Chem. Lett."},{"key":"204_CR44","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658\u2013674 (2007).","journal-title":"J. Appl. Crystallogr."},{"key":"204_CR45","first-page":"213","volume-title":"Acta Crystallogr. D Biol. Crystallogr.","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, (213\u2013221 (2010)."},{"key":"204_CR46","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D. Biol. Crystallogr. 60, 2126\u20132132 (2004).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"204_CR47","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1107\/S0907444912001308","volume":"68","author":"PV Afonine","year":"2012","unstructured":"Afonine, P. V. et al. Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr. D. Biol. Crystallogr. 68, 352\u2013367 (2012).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"204_CR48","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1021\/ci200227u","volume":"51","author":"RA Laskowski","year":"2011","unstructured":"Laskowski, R. A. & Swindells, M. B. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model. 51, 2778\u20132786 (2011).","journal-title":"J. Chem. Inf. Model."},{"key":"204_CR49","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1158\/0008-5472.CAN-16-1593","volume":"77","author":"T Shibata","year":"2017","unstructured":"Shibata, T. et al. Breast cancer resistance to antiestrogens is enhanced by increased ER degradation and ERBB2 expression. Cancer Res. 77, 545\u2013556 (2017).","journal-title":"Cancer Res."},{"key":"204_CR50","doi-asserted-by":"publisher","first-page":"47403","DOI":"10.18632\/oncotarget.10161","volume":"7","author":"K Watari","year":"2016","unstructured":"Watari, K. et al. Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma. Oncotarget 7, 47403\u201347417 (2016).","journal-title":"Oncotarget"},{"key":"204_CR51","doi-asserted-by":"crossref","unstructured":"Ackley, D. C., Rockich, K. T. & Baker, T. R. in Optimization in Drug Discovery 151\u2012162 (Humana Press Inc., Totowa, NJ, 2004).","DOI":"10.1385\/1-59259-800-5:151"}],"container-title":["Nature Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41589-018-0204-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41589-018-0204-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41589-018-0204-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T22:26:49Z","timestamp":1684621609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41589-018-0204-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,14]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["204"],"URL":"https:\/\/doi.org\/10.1038\/s41589-018-0204-3","relation":{},"ISSN":["1552-4450","1552-4469"],"issn-type":[{"value":"1552-4450","type":"print"},{"value":"1552-4469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,14]]},"assertion":[{"value":"15 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}